Table 1. Clinical, biochemical, virological, and pathological characteristics of the study population.
| Variable | EPCI (N=49) | EPCH (N=243) | Z* | χ2,† | P‡ | ENCI (N=101) | ENCH (N=99) | Z* | χ2,† | P§ |
|---|---|---|---|---|---|---|---|---|---|---|
| Sex (male:female) | 27 : 22 | 162 : 81 | 1.909 | 0.1671 | 56 : 45 | 68 : 31 | 3.180 | 0.0746 | ||
| Age (year) | 33, 27–40 | 32, 27–40 | 0.395 | 0.6927 | 42, 32–49 | 44, 36–52 | 1.693 | 0.0905 | ||
| Serum ALT (µkat/L) | 0.391, 0.153–0.663 | 1.496, 0.272–30.379 | 10.445 | < 0.0001 | 0.323, 0.085–0.663 | 1.530, 0.306–24.446 | 11.413 | < 0.0001 | ||
| Serum AST (µkat/L) | 0.367, 0.200–0.651 | 1.002, 0.284–18.220 | 10.264 | < 0.0001 | 0.351, 0.217–0.635 | 0.952, 0.267–12.542 | 11.026 | < 0.0001 | ||
| Serum ALB (mmol/L) | 0.639, 0.512–0.758 | 0.635, 0.363–0.784 | 0.868 | 0.3854 | 0.662, 0.430–0.831 | 0.633, 0.393–0.889 | 3.707 | 0.0002 | ||
| Serum ChE (µkat/L) | 134.500, 65.300–195.300 | 120.1, 14.6–274.2 | 2.395 | 0.0166 | 128.8, 85.5–353.8 | 122.5, 25.5–252.7 | 2.825 | 0.0047 | ||
| Blood PLT ( × 109/L) | 163, 148–198 | 158, 120–190 | 1.944 | 0.0519 | 158, 126–188 | 128, 96–159 | 4.040 | 0.0001 | ||
| Serum HBcrAg (log10 kU/mL) | 5.502, 5.201–5.668 | 4.810, 3.789–5.459 | 5.248 | < 0.0001 | < 0.000, < 0.000–0.394 | 2.163, 1.045–2.879 | 9.639 | < 0.0001 | ||
| Serum HBsAg (log10 IU/mL) | 4.735, 4.489–4.978 | 3.945, 3.428–4.573 | 6.881 | < 0.0001 | 3.098, 1.993–3.612 | 3.221, 2.821–3.655 | 1.980 | 0.0477 | ||
| Serum HBeAg (log10 SCO) | 3.119, 3.025–3.169 | 2.696, 1.725–3.091 | 5.906 | < 0.0001 | - | - | - | - | ||
| Serum HBV DNA (log10 IU/mL) | > 7.699, 7.655– > 7.699 | 7.407, 6.240– > 7.699 | 4.999 | < 0.0001 | < 2.699, < 2.699 -3.318 | 5.535, 4.326–6.253 | 11.769 | < 0.0001 | ||
| Intrahepatic HBsAg | ||||||||||
| 0:1:2:3 | 0:9:25:15 | 5:54:85:99 | 5.146 | 0.1614 | 13:41:31:16 | 3:23:45:28 | 17.146 | 0.0007 | ||
| ≥ 1 (%) | 49 (100) | 238 (97.9) | 0.167 | 0.6823 | 88 (87.1) | 96 (97.0) | 5.309 | 0.0212 | ||
| ≥ 2 (%) | 40 (81.6) | 184 (75.7) | 0.501 | 0.4789 | 47 (46.5) | 73 (73.7) | 14.302 | 0.0002 | ||
| ≥ 3 (%) | 15 (30.6) | 99 (40.7) | 1.358 | 0.2439 | 16 (15.8) | 28 (28.3) | 3.814 | 0.0508 | ||
| Intrahepatic HBcAg | ||||||||||
| 0:1:2:3 | 13:18:18:0 | 152:69:22:0 | 33.124 | < 0.0001 | 97:3:1:0 | 91:7:1:0 | 1.772 | 0.4124 | ||
| ≥ 1 (%) | 36 (73.5) | 91 (37.4) | 20.087 | < 0.0001 | 4 (4.0) | 8 (8.1) | 0.863 | 0.3529 | ||
| ≥ 2 (%) | 18 (36.7) | 22 (9.1) | 24.140 | < 0.0001 | 1 (1.0) | 1 (1.0) | 0.485 | 0.4861 | ||
| Pathological grade | ||||||||||
| ≤1:2:3:4 | 49:0:0:0 | 85:77:81:0 | 69.426 | <0.0001 | 101:0:0:0 | 35:35:29:0 | 96.019 | <0.0001 | ||
| Pathological stage | ||||||||||
| ≤1:2:3:4 | 49:0:0:0 | 72:74:38:59 | 83.212 | <0.0001 | 79:6:4:2 | 24:32:19:24 | <0.0001 |
Continous data are presented as median (range),and categorical data are presented as N (%).
*Two-independent samples Mann-Whitney U test; †Pearson's chi-square test; ‡EPCI vs EPCH; §ENCI vs ENCH.
Abbreviations: HBeAg, hepatitis B e antigen; EPCI, HBeAg-positive chronic infection; EPCH, HBeAg-positive chronic hepatitis; ENCI, HBeAg-negative chronic infection; ENCH, HBeAg-negative chronic hepatitis; ALT, alanine transferase; AST, aspartate transferase; ALB, albumin; ChE, cholinesterase; PLT, platelet; HBcrAg, hepatitis B core-related antigen; HBsAg, hepatitis B surface antigen; HBV DNA, hepatitis B virus DNA; HBcrAg, hepatitis B core antigen.